在痛风发作住院期间实施达标治疗降尿酸策略
前瞻性队列研究评估住院痛风管理联合护士随访及转诊初级保健的策略,比较实施后12个月与实施前12个月住院痛风患者的降尿酸治疗启动率、尿酸达标率及再住院率。实施后新启动降尿酸治疗比例从49.2%升至92.3%(aOR 11.5),6个月内血尿酸≤360 μmol/l比例从10.6%升至26.8%(aOR 3.04),再住院率无显著差异。
要点
- 实施后新启动降尿酸治疗比例从49.2%升至92.3%(aOR 11.5,95%CI 4.36-30.5,P<0.001)。
- 实施后6个月内血尿酸≤360 μmol/l比例从10.6%升至26.8%(aOR 3.04,95%CI 1.36-6.78,P=0.007)。
- 再住院率实施前14.9% vs 实施后9.3%(aOR 0.53,95%CI 0.22-1.32,P=0.18),无显著差异。
核心结论
- 实施优化住院痛风管理的策略后,超过90%的患者启动降尿酸治疗。
- 尽管痛风发作期间降尿酸治疗启动增加,实施后再住院频率未增加。
- 尿酸达标率相对改善显著,但多数住院痛风患者仍需更紧密的初级-二级医疗整合才能达标。
研究设计与样本
- 前瞻性队列研究,评估结合住院痛风优化管理、护士主导随访预约及转诊初级保健的策略。
- 比较实施后12个月住院痛风发作患者(n=108)与实施前12个月回顾性队列(n=119)。
- 有6个月随访数据的患者分别为实施前n=94和实施后n=97。
主要发现
- 实施前12个月119例、实施后12个月108例患者因痛风发作住院。
- 有6个月随访数据者中,新启动降尿酸治疗比例从实施前49.2%升至实施后92.3%(aOR 11.5;95%CI 4.36,30.5;P<0.001)。
- 出院6个月内血尿酸≤360 μmol/l比例实施前10.6% vs 实施后26.8%(aOR 3.04;95%CI 1.36,6.78;P=0.007)。
- 因痛风发作再住院比例实施前14.9% vs 实施后9.3%(aOR 0.53;95%CI 0.22,1.32;P=0.18)。
关键数值与推荐
- 新启动降尿酸治疗:实施前49.2% vs 实施后92.3%(aOR 11.5;95%CI 4.36,30.5;P<0.001)。
- 6个月内血尿酸≤360 μmol/l:实施前10.6% vs 实施后26.8%(aOR 3.04;95%CI 1.36,6.78;P=0.007)。
- 痛风发作再住院:实施前14.9% vs 实施后9.3%(aOR 0.53;95%CI 0.22,1.32;P=0.18)。
临床怎么用
- 实施优化住院痛风管理联合护士主导随访及转诊初级保健的策略后,超过90%的患者启动降尿酸治疗。
- 作者认为,为使多数住院痛风患者达到尿酸目标,仍需更紧密的初级-二级医疗整合。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate a strategy designed to optimize care and increase uptake of urate-lowering therapy (ULT) during hospitalizations for gout flares. METHODS: We conducted a prospective cohort study to evaluate a strategy that combined optimal in-hospital gout management with a nurse-led, follow-up appointment, followed by handover to primary care. Outcomes, including ULT initiation, urate target attainment and re-hospitalization rates, were compared between patients hospitalized for flares in the 12 months post-implementation and a retrospective cohort of hospitalized patients from 12 months pre-implementation. RESULTS: One hundred and nineteen and 108 patients, respectively, were hospitalized for gout flares in the 12 months pre- and post-implementation. For patients with 6-month follow-up data available (n = 94 and n = 97, respectively), the proportion newly initiated on ULT increased from 49.2% pre-implementation to 92.3% post-implementation (age/sex-adjusted odds ratio [aOR] 11.5; 95% CI 4.36, 30.5; P < 0.001). After implementation, more patients achieved a serum urate ≤360 μmol/l within 6 months of discharge (10.6% pre-implementation vs 26.8% post-implementation; aOR 3.04; 95% CI 1.36, 6.78; P = 0.007). The proportion of patients re-hospitalized for flares was 14.9% pre-implementation vs 9.3% post-implementation (aOR 0.53; 95% CI 0.22, 1.32; P = 0.18). CONCLUSION: Over 90% of patients were initiated on ULT after implementing a strategy to optimize hospital gout care. Despite increased initiation of ULT during flares, recurrent hospitalizations were not more frequent following implementation. Significant relative improvements in urate target attainment were observed post-implementation; however, for the majority of hospitalized gout patients to achieve urate targets, closer primary-secondary care integration is still needed.
引用
- Russell MD, Ameyaw-Kyeremeh L, Dell'Accio F, et al. Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares. Rheumatology (Oxford). 2024. PMID: 37929968. doi:10.1093/rheumatology/kead574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。